EKSO COO tax-withholding sale: 9,723 shares; 27,211 held post-sale

Rhea-AI Filing Summary

Ekso Bionics (EKSO) reported an insider transaction by its Chief Operating Officer. On 11/10/2025, the executive sold 9,723 shares of common stock in a single transaction at $4.7990 per share. The filing states the sale was made to cover tax withholding obligations arising from the vesting and settlement of previously reported restricted stock awards.

Following the sale, the reporting person beneficially owns 27,211 shares directly and 3,141 shares indirectly through a 401(k). The company effected a 1‑for‑15 reverse stock split on June 2, 2025, and the reported amounts reflect that adjustment.

Insider Trade Summary

Net Seller: 9,723 shares ($46,670)

Net Sell 2 txns

Insider Jones Jason C

Role Chief Operating Officer

Sold 9,723 shs ($47K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,723	$4.80	$47K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 27,211 shares (Direct); Common Stock — 3,141 shares (Indirect, By 401(k))

Footnotes (1)

1. Represents shares sold by the Reporting Person on November 10, 2025 to cover tax withholding obligations incurred upon the vesting and settlement of restricted stock awards originally reported by the Reporting Person in Form 4 filed with the Commission on November 7, 2025. These shares were sold in a single transaction at a price of $4.7990 per share. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Jason C

(Last) (First) (Middle)

101 GLACIER POINT

SUITE A

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [ EKSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/10/2025		S		9,723(1)	D	$4.8(2)	27,211(3)	D
Common Stock								3,141(3)	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person on November 10, 2025 to cover tax withholding obligations incurred upon the vesting and settlement of restricted stock awards originally reported by the Reporting Person in Form 4 filed with the Commission on November 7, 2025.

2. These shares were sold in a single transaction at a price of $4.7990 per share.

3. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

	/s/ Jerome Wong	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Ekso Bionics (EKSO) disclose in this Form 4?

The COO sold 9,723 shares on 11/10/2025 at $4.7990 per share to cover tax withholding from vested restricted stock.

How many EKSO shares does the insider own after the transaction?

Beneficial ownership is 27,211 shares directly and 3,141 shares indirectly via a 401(k).

What was the sale price for the EKSO shares?

The shares were sold in a single transaction at $4.7990 per share.

Why were the EKSO shares sold by the insider?

The sale covered tax withholding obligations related to the vesting and settlement of restricted stock awards.

Does the filing reflect any stock split adjustments?

Yes. Amounts reflect Ekso Bionics’ 1‑for‑15 reverse stock split effective June 2, 2025.

What is the insider’s role at Ekso Bionics (EKSO)?

The reporting person is the company’s Chief Operating Officer.